The pharmacokinetic characteristics of belinostat were analyzed from pooled data from phase 1/2 clinical studies that used doses of belinostat ranging from 150 to 1200 mg/m2 (0.15 to 1.2 times the approved recommended dosage).
Distribution
The mean belinostat volume of distribution approaches total body water, indicating that belinostat has limited body tissue distribution. In vitro plasma studies have shown that between 92.9% and 95.8% of belinostat is bound to protein in an equilibrium dialysis assay, and was independent of belinostat plasma concentrations from 500 to 25,000 ng/mL.
Elimination
Belinostat elimination half-life is 1.1 hours with a total mean plasma clearance of 1240 mL/min. The total clearance approximates average hepatic blood flow (1500 mL/min), suggesting high hepatic extraction (clearance being flow dependent).
Metabolism
Belinostat is primarily metabolized by hepatic UGT1A1. Belinostat also undergoes hepatic metabolism by CYP2A6, CYP2C9, and CYP3A4 enzymes.
Excretion
Following a single dose of radiolabeled belinostat (100 μCi, 1500 mg) administered as a 30-minute intravenous infusion in patients with recurrent or progressive malignancy, fecal excretion accounted for a mean (± SD) of 9.7% (± 6.5%) of the administered radioactive belinostat dose over 168 hours. The mean (± SD) of the administered radioactive belinostat dose that was excreted in urine over 168 hours was 84.8% (± 9.8%), of which unchanged belinostat accounted for only 1.7%.
Specific Populations
Hepatic Impairment
Belinostat steady state clearance decreased and AUC increased as a function of the degree of liver dysfunction, but were unchanged for Cmax, half‐life and apparent volume of distribution. Mean belinostat clearance was reduced by 18% in mild (total bilirubin ≤ ULN and AST >ULN, or total bilirubin ˃1 to 1.5 x ULN), 24% in moderate (total bilirubin ˃ 1.5 to 3 times ULN and any value for AST) and 33% in severe hepatic impairment (total bilirubin ˃ 3 to 10 times ULN and any value for AST). Increases in belinostat exposure were correlated with worsening liver function, but there was no obvious relationship between exposure and DLTs during the first cycle of therapy.
Renal Impairment
Belinostat Cmax increased by 1.7-fold, AUC0-∞ by 1.3-fold and CLtot was unchanged in patients with mild renal impairment (CLcr 60 to <90 ml/min). Belinostat Cmax and AUC0-∞ increased by 1.7-fold and CLtot decreased by 26% in patients with moderate renal impairment (CLcr 30 < 60 ml/min). The effect of severe renal impairment (CLcr < 30 mL/min) on belinostat pharmacokinetics is unknown.
Drug Interaction Studies
Clinical Studies and Model-Informed Approaches
UGT1A1 inhibitors: Belinostat t1/2 increased by 1.5-fold, AUC0-inf increased by 1.4-fold, Cmax decreased by 33%, and renal excretion increased by 2.5-fold following concomitant administration with atazanavir (UGT1A1 inhibitor), but there was minimal change in steady state clearance. There was minimal change in belinostat glucuronide Cmax, AUC0-24; however, belinostat glucuronide excretion decreased by 48%.
Warfarin: No clinically significant differences in the pharmacokinetics of R- or S-warfarin were observed when used concomitantly with belinostat.
In Vitro Studies
CYP450 Enzymes: Belinostat and its metabolites are CYP2C8 and CYP2C9 inhibitors.
Transporter Systems: Belinostat is a glycoprotein (P-gp) substrate but is not a P-gp inhibitor.